nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—FDPS—jaw skeleton—bone cancer	0.129	0.465	CbGeAlD
Ibandronate—FDPS—periosteum—bone cancer	0.0977	0.351	CbGeAlD
Ibandronate—FDPS—connective tissue—bone cancer	0.017	0.0612	CbGeAlD
Ibandronate—FDPS—tendon—bone cancer	0.0117	0.042	CbGeAlD
Ibandronate—FDPS—bone marrow—bone cancer	0.0113	0.0407	CbGeAlD
Ibandronate—FDPS—spinal cord—bone cancer	0.0113	0.0405	CbGeAlD
Ibandronate—Risedronate—PTGS2—bone cancer	0.00762	1	CrCbGaD
Ibandronate—Skin disorder—Cisplatin—bone cancer	0.00166	0.00232	CcSEcCtD
Ibandronate—Pain in extremity—Doxorubicin—bone cancer	0.00165	0.00231	CcSEcCtD
Ibandronate—Osteoarthritis—Doxorubicin—bone cancer	0.00165	0.00231	CcSEcCtD
Ibandronate—Hyperhidrosis—Cisplatin—bone cancer	0.00165	0.00231	CcSEcCtD
Ibandronate—Asthma—Methotrexate—bone cancer	0.00165	0.00231	CcSEcCtD
Ibandronate—Abdominal pain upper—Epirubicin—bone cancer	0.00163	0.00228	CcSEcCtD
Ibandronate—Migraine—Doxorubicin—bone cancer	0.00162	0.00228	CcSEcCtD
Ibandronate—Breast disorder—Epirubicin—bone cancer	0.00161	0.00226	CcSEcCtD
Ibandronate—Nasopharyngitis—Epirubicin—bone cancer	0.0016	0.00223	CcSEcCtD
Ibandronate—Face oedema—Doxorubicin—bone cancer	0.00159	0.00223	CcSEcCtD
Ibandronate—Abdominal discomfort—Methotrexate—bone cancer	0.00158	0.00221	CcSEcCtD
Ibandronate—Gastritis—Epirubicin—bone cancer	0.00158	0.00221	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00156	0.00218	CcSEcCtD
Ibandronate—Blood creatinine increased—Doxorubicin—bone cancer	0.00155	0.00217	CcSEcCtD
Ibandronate—Influenza—Epirubicin—bone cancer	0.00154	0.00216	CcSEcCtD
Ibandronate—Asthma—Epirubicin—bone cancer	0.00154	0.00216	CcSEcCtD
Ibandronate—Dysphagia—Epirubicin—bone cancer	0.00154	0.00216	CcSEcCtD
Ibandronate—Paraesthesia—Cisplatin—bone cancer	0.00153	0.00215	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Methotrexate—bone cancer	0.00153	0.00215	CcSEcCtD
Ibandronate—Abdominal pain upper—Doxorubicin—bone cancer	0.00151	0.00211	CcSEcCtD
Ibandronate—Breast disorder—Doxorubicin—bone cancer	0.00149	0.00209	CcSEcCtD
Ibandronate—Decreased appetite—Cisplatin—bone cancer	0.00148	0.00208	CcSEcCtD
Ibandronate—Bronchitis—Epirubicin—bone cancer	0.00148	0.00208	CcSEcCtD
Ibandronate—Pneumonia—Methotrexate—bone cancer	0.00148	0.00207	CcSEcCtD
Ibandronate—Nasopharyngitis—Doxorubicin—bone cancer	0.00148	0.00207	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Cisplatin—bone cancer	0.00147	0.00206	CcSEcCtD
Ibandronate—Infestation NOS—Methotrexate—bone cancer	0.00147	0.00206	CcSEcCtD
Ibandronate—Infestation—Methotrexate—bone cancer	0.00147	0.00206	CcSEcCtD
Ibandronate—Depression—Methotrexate—bone cancer	0.00146	0.00205	CcSEcCtD
Ibandronate—Gastritis—Doxorubicin—bone cancer	0.00146	0.00205	CcSEcCtD
Ibandronate—Pain—Cisplatin—bone cancer	0.00146	0.00205	CcSEcCtD
Ibandronate—Renal failure—Methotrexate—bone cancer	0.00144	0.00202	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Epirubicin—bone cancer	0.00143	0.00201	CcSEcCtD
Ibandronate—Stomatitis—Methotrexate—bone cancer	0.00143	0.00201	CcSEcCtD
Ibandronate—Dysphagia—Doxorubicin—bone cancer	0.00143	0.002	CcSEcCtD
Ibandronate—Influenza—Doxorubicin—bone cancer	0.00143	0.002	CcSEcCtD
Ibandronate—Asthma—Doxorubicin—bone cancer	0.00143	0.002	CcSEcCtD
Ibandronate—Sweating—Methotrexate—bone cancer	0.00141	0.00197	CcSEcCtD
Ibandronate—Feeling abnormal—Cisplatin—bone cancer	0.00141	0.00197	CcSEcCtD
Ibandronate—Weight decreased—Epirubicin—bone cancer	0.00139	0.00195	CcSEcCtD
Ibandronate—Hepatobiliary disease—Methotrexate—bone cancer	0.00139	0.00195	CcSEcCtD
Ibandronate—Pneumonia—Epirubicin—bone cancer	0.00138	0.00194	CcSEcCtD
Ibandronate—Infestation—Epirubicin—bone cancer	0.00137	0.00193	CcSEcCtD
Ibandronate—Infestation NOS—Epirubicin—bone cancer	0.00137	0.00193	CcSEcCtD
Ibandronate—Bronchitis—Doxorubicin—bone cancer	0.00137	0.00192	CcSEcCtD
Ibandronate—Renal failure—Epirubicin—bone cancer	0.00135	0.00189	CcSEcCtD
Ibandronate—Body temperature increased—Cisplatin—bone cancer	0.00135	0.00189	CcSEcCtD
Ibandronate—Stomatitis—Epirubicin—bone cancer	0.00134	0.00188	CcSEcCtD
Ibandronate—Urinary tract infection—Epirubicin—bone cancer	0.00134	0.00187	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00133	0.00186	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—bone cancer	0.00133	0.00186	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—bone cancer	0.00132	0.00185	CcSEcCtD
Ibandronate—Sweating—Epirubicin—bone cancer	0.00132	0.00185	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—bone cancer	0.00131	0.00183	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—bone cancer	0.0013	0.00182	CcSEcCtD
Ibandronate—Hepatobiliary disease—Epirubicin—bone cancer	0.0013	0.00182	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—bone cancer	0.00129	0.00181	CcSEcCtD
Ibandronate—Weight decreased—Doxorubicin—bone cancer	0.00129	0.00181	CcSEcCtD
Ibandronate—Pneumonia—Doxorubicin—bone cancer	0.00128	0.00179	CcSEcCtD
Ibandronate—Infestation NOS—Doxorubicin—bone cancer	0.00127	0.00178	CcSEcCtD
Ibandronate—Infestation—Doxorubicin—bone cancer	0.00127	0.00178	CcSEcCtD
Ibandronate—Hypersensitivity—Cisplatin—bone cancer	0.00126	0.00176	CcSEcCtD
Ibandronate—Renal failure—Doxorubicin—bone cancer	0.00125	0.00175	CcSEcCtD
Ibandronate—Haemoglobin—Epirubicin—bone cancer	0.00124	0.00174	CcSEcCtD
Ibandronate—Stomatitis—Doxorubicin—bone cancer	0.00124	0.00174	CcSEcCtD
Ibandronate—Urinary tract infection—Doxorubicin—bone cancer	0.00124	0.00173	CcSEcCtD
Ibandronate—Haemorrhage—Epirubicin—bone cancer	0.00123	0.00173	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—bone cancer	0.00123	0.00173	CcSEcCtD
Ibandronate—Asthenia—Cisplatin—bone cancer	0.00122	0.00172	CcSEcCtD
Ibandronate—Pharyngitis—Epirubicin—bone cancer	0.00122	0.00172	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—bone cancer	0.00122	0.00171	CcSEcCtD
Ibandronate—Sweating—Doxorubicin—bone cancer	0.00122	0.00171	CcSEcCtD
Ibandronate—Urinary tract disorder—Epirubicin—bone cancer	0.00122	0.00171	CcSEcCtD
Ibandronate—Oedema peripheral—Epirubicin—bone cancer	0.00122	0.0017	CcSEcCtD
Ibandronate—Connective tissue disorder—Epirubicin—bone cancer	0.00121	0.0017	CcSEcCtD
Ibandronate—Urethral disorder—Epirubicin—bone cancer	0.00121	0.00169	CcSEcCtD
Ibandronate—Hepatobiliary disease—Doxorubicin—bone cancer	0.0012	0.00169	CcSEcCtD
Ibandronate—Angiopathy—Methotrexate—bone cancer	0.0012	0.00168	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—bone cancer	0.00119	0.00167	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—bone cancer	0.00119	0.00166	CcSEcCtD
Ibandronate—Chills—Methotrexate—bone cancer	0.00118	0.00166	CcSEcCtD
Ibandronate—Diarrhoea—Cisplatin—bone cancer	0.00117	0.00164	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—bone cancer	0.00117	0.00163	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—bone cancer	0.00116	0.00162	CcSEcCtD
Ibandronate—Eye disorder—Epirubicin—bone cancer	0.00115	0.00162	CcSEcCtD
Ibandronate—Erythema—Methotrexate—bone cancer	0.00115	0.00161	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—bone cancer	0.00115	0.00161	CcSEcCtD
Ibandronate—Haemoglobin—Doxorubicin—bone cancer	0.00115	0.00161	CcSEcCtD
Ibandronate—Cardiac disorder—Epirubicin—bone cancer	0.00115	0.0016	CcSEcCtD
Ibandronate—Haemorrhage—Doxorubicin—bone cancer	0.00114	0.0016	CcSEcCtD
Ibandronate—Pharyngitis—Doxorubicin—bone cancer	0.00113	0.00159	CcSEcCtD
Ibandronate—Urinary tract disorder—Doxorubicin—bone cancer	0.00113	0.00158	CcSEcCtD
Ibandronate—Oedema peripheral—Doxorubicin—bone cancer	0.00112	0.00158	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—bone cancer	0.00112	0.00157	CcSEcCtD
Ibandronate—Connective tissue disorder—Doxorubicin—bone cancer	0.00112	0.00157	CcSEcCtD
Ibandronate—Angiopathy—Epirubicin—bone cancer	0.00112	0.00157	CcSEcCtD
Ibandronate—Urethral disorder—Doxorubicin—bone cancer	0.00112	0.00157	CcSEcCtD
Ibandronate—Immune system disorder—Epirubicin—bone cancer	0.00111	0.00156	CcSEcCtD
Ibandronate—Mediastinal disorder—Epirubicin—bone cancer	0.00111	0.00156	CcSEcCtD
Ibandronate—Back pain—Methotrexate—bone cancer	0.00111	0.00156	CcSEcCtD
Ibandronate—Chills—Epirubicin—bone cancer	0.00111	0.00155	CcSEcCtD
Ibandronate—Alopecia—Epirubicin—bone cancer	0.00109	0.00153	CcSEcCtD
Ibandronate—Vomiting—Cisplatin—bone cancer	0.00109	0.00152	CcSEcCtD
Ibandronate—Mental disorder—Epirubicin—bone cancer	0.00108	0.00151	CcSEcCtD
Ibandronate—Rash—Cisplatin—bone cancer	0.00108	0.00151	CcSEcCtD
Ibandronate—Dermatitis—Cisplatin—bone cancer	0.00108	0.00151	CcSEcCtD
Ibandronate—Erythema—Epirubicin—bone cancer	0.00107	0.00151	CcSEcCtD
Ibandronate—Malnutrition—Epirubicin—bone cancer	0.00107	0.00151	CcSEcCtD
Ibandronate—Eye disorder—Doxorubicin—bone cancer	0.00107	0.00149	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—bone cancer	0.00107	0.00149	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—bone cancer	0.00106	0.00149	CcSEcCtD
Ibandronate—Cardiac disorder—Doxorubicin—bone cancer	0.00106	0.00148	CcSEcCtD
Ibandronate—Flatulence—Epirubicin—bone cancer	0.00106	0.00148	CcSEcCtD
Ibandronate—Dysgeusia—Epirubicin—bone cancer	0.00105	0.00147	CcSEcCtD
Ibandronate—Back pain—Epirubicin—bone cancer	0.00104	0.00146	CcSEcCtD
Ibandronate—Angiopathy—Doxorubicin—bone cancer	0.00104	0.00145	CcSEcCtD
Ibandronate—Malaise—Methotrexate—bone cancer	0.00104	0.00145	CcSEcCtD
Ibandronate—Muscle spasms—Epirubicin—bone cancer	0.00103	0.00145	CcSEcCtD
Ibandronate—Immune system disorder—Doxorubicin—bone cancer	0.00103	0.00144	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—bone cancer	0.00103	0.00144	CcSEcCtD
Ibandronate—Mediastinal disorder—Doxorubicin—bone cancer	0.00103	0.00144	CcSEcCtD
Ibandronate—Chills—Doxorubicin—bone cancer	0.00102	0.00144	CcSEcCtD
Ibandronate—Nausea—Cisplatin—bone cancer	0.00101	0.00142	CcSEcCtD
Ibandronate—Alopecia—Doxorubicin—bone cancer	0.00101	0.00141	CcSEcCtD
Ibandronate—Mental disorder—Doxorubicin—bone cancer	0.001	0.0014	CcSEcCtD
Ibandronate—Ill-defined disorder—Epirubicin—bone cancer	0.000997	0.0014	CcSEcCtD
Ibandronate—Erythema—Doxorubicin—bone cancer	0.000994	0.00139	CcSEcCtD
Ibandronate—Malnutrition—Doxorubicin—bone cancer	0.000994	0.00139	CcSEcCtD
Ibandronate—Anaemia—Epirubicin—bone cancer	0.000993	0.00139	CcSEcCtD
Ibandronate—Flatulence—Doxorubicin—bone cancer	0.000979	0.00137	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—bone cancer	0.000977	0.00137	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—bone cancer	0.000977	0.00137	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—bone cancer	0.000977	0.00137	CcSEcCtD
Ibandronate—Dysgeusia—Doxorubicin—bone cancer	0.000973	0.00136	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000971	0.00136	CcSEcCtD
Ibandronate—Malaise—Epirubicin—bone cancer	0.000969	0.00136	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—bone cancer	0.000966	0.00135	CcSEcCtD
Ibandronate—Vertigo—Epirubicin—bone cancer	0.000965	0.00135	CcSEcCtD
Ibandronate—Back pain—Doxorubicin—bone cancer	0.000961	0.00135	CcSEcCtD
Ibandronate—Muscle spasms—Doxorubicin—bone cancer	0.000956	0.00134	CcSEcCtD
Ibandronate—Palpitations—Epirubicin—bone cancer	0.000949	0.00133	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—bone cancer	0.000937	0.00131	CcSEcCtD
Ibandronate—Infection—Methotrexate—bone cancer	0.000931	0.0013	CcSEcCtD
Ibandronate—Hypertension—Epirubicin—bone cancer	0.000927	0.0013	CcSEcCtD
Ibandronate—Ill-defined disorder—Doxorubicin—bone cancer	0.000922	0.00129	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—bone cancer	0.000919	0.00129	CcSEcCtD
Ibandronate—Anaemia—Doxorubicin—bone cancer	0.000919	0.00129	CcSEcCtD
Ibandronate—Myalgia—Epirubicin—bone cancer	0.000915	0.00128	CcSEcCtD
Ibandronate—Chest pain—Epirubicin—bone cancer	0.000915	0.00128	CcSEcCtD
Ibandronate—Arthralgia—Epirubicin—bone cancer	0.000915	0.00128	CcSEcCtD
Ibandronate—Anxiety—Epirubicin—bone cancer	0.000911	0.00128	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—bone cancer	0.00091	0.00127	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000908	0.00127	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—bone cancer	0.000906	0.00127	CcSEcCtD
Ibandronate—Discomfort—Epirubicin—bone cancer	0.000904	0.00127	CcSEcCtD
Ibandronate—Malaise—Doxorubicin—bone cancer	0.000896	0.00126	CcSEcCtD
Ibandronate—Dry mouth—Epirubicin—bone cancer	0.000894	0.00125	CcSEcCtD
Ibandronate—Vertigo—Doxorubicin—bone cancer	0.000893	0.00125	CcSEcCtD
Ibandronate—Palpitations—Doxorubicin—bone cancer	0.000878	0.00123	CcSEcCtD
Ibandronate—Anaphylactic shock—Epirubicin—bone cancer	0.000877	0.00123	CcSEcCtD
Ibandronate—Infection—Epirubicin—bone cancer	0.000871	0.00122	CcSEcCtD
Ibandronate—Shock—Epirubicin—bone cancer	0.000863	0.00121	CcSEcCtD
Ibandronate—Nervous system disorder—Epirubicin—bone cancer	0.00086	0.0012	CcSEcCtD
Ibandronate—Hypertension—Doxorubicin—bone cancer	0.000858	0.0012	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000854	0.0012	CcSEcCtD
Ibandronate—Skin disorder—Epirubicin—bone cancer	0.000852	0.00119	CcSEcCtD
Ibandronate—Hyperhidrosis—Epirubicin—bone cancer	0.000848	0.00119	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—bone cancer	0.000847	0.00119	CcSEcCtD
Ibandronate—Myalgia—Doxorubicin—bone cancer	0.000846	0.00119	CcSEcCtD
Ibandronate—Arthralgia—Doxorubicin—bone cancer	0.000846	0.00119	CcSEcCtD
Ibandronate—Chest pain—Doxorubicin—bone cancer	0.000846	0.00119	CcSEcCtD
Ibandronate—Anxiety—Doxorubicin—bone cancer	0.000843	0.00118	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—bone cancer	0.000841	0.00118	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00084	0.00118	CcSEcCtD
Ibandronate—Discomfort—Doxorubicin—bone cancer	0.000836	0.00117	CcSEcCtD
Ibandronate—Dry mouth—Doxorubicin—bone cancer	0.000828	0.00116	CcSEcCtD
Ibandronate—Dyspepsia—Methotrexate—bone cancer	0.000825	0.00116	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—bone cancer	0.000814	0.00114	CcSEcCtD
Ibandronate—Anaphylactic shock—Doxorubicin—bone cancer	0.000811	0.00114	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—bone cancer	0.000809	0.00113	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—bone cancer	0.000808	0.00113	CcSEcCtD
Ibandronate—Infection—Doxorubicin—bone cancer	0.000806	0.00113	CcSEcCtD
Ibandronate—Pain—Methotrexate—bone cancer	0.000801	0.00112	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000799	0.00112	CcSEcCtD
Ibandronate—Shock—Doxorubicin—bone cancer	0.000798	0.00112	CcSEcCtD
Ibandronate—Nervous system disorder—Doxorubicin—bone cancer	0.000796	0.00111	CcSEcCtD
Ibandronate—Insomnia—Epirubicin—bone cancer	0.000793	0.00111	CcSEcCtD
Ibandronate—Skin disorder—Doxorubicin—bone cancer	0.000788	0.0011	CcSEcCtD
Ibandronate—Paraesthesia—Epirubicin—bone cancer	0.000787	0.0011	CcSEcCtD
Ibandronate—Hyperhidrosis—Doxorubicin—bone cancer	0.000784	0.0011	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—bone cancer	0.000772	0.00108	CcSEcCtD
Ibandronate—Dyspepsia—Epirubicin—bone cancer	0.000772	0.00108	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methotrexate—bone cancer	0.000766	0.00107	CcSEcCtD
Ibandronate—Decreased appetite—Epirubicin—bone cancer	0.000762	0.00107	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Epirubicin—bone cancer	0.000757	0.00106	CcSEcCtD
Ibandronate—Fatigue—Epirubicin—bone cancer	0.000756	0.00106	CcSEcCtD
Ibandronate—Pain—Epirubicin—bone cancer	0.00075	0.00105	CcSEcCtD
Ibandronate—Constipation—Epirubicin—bone cancer	0.00075	0.00105	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—bone cancer	0.000744	0.00104	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—bone cancer	0.000741	0.00104	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—bone cancer	0.000741	0.00104	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000739	0.00104	CcSEcCtD
Ibandronate—Insomnia—Doxorubicin—bone cancer	0.000734	0.00103	CcSEcCtD
Ibandronate—Paraesthesia—Doxorubicin—bone cancer	0.000728	0.00102	CcSEcCtD
Ibandronate—Feeling abnormal—Epirubicin—bone cancer	0.000722	0.00101	CcSEcCtD
Ibandronate—Gastrointestinal pain—Epirubicin—bone cancer	0.000717	0.001	CcSEcCtD
Ibandronate—Dyspepsia—Doxorubicin—bone cancer	0.000714	0.001	CcSEcCtD
Ibandronate—Decreased appetite—Doxorubicin—bone cancer	0.000705	0.000988	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Doxorubicin—bone cancer	0.0007	0.000981	CcSEcCtD
Ibandronate—Fatigue—Doxorubicin—bone cancer	0.000699	0.00098	CcSEcCtD
Ibandronate—Urticaria—Epirubicin—bone cancer	0.000697	0.000976	CcSEcCtD
Ibandronate—Constipation—Doxorubicin—bone cancer	0.000694	0.000972	CcSEcCtD
Ibandronate—Pain—Doxorubicin—bone cancer	0.000694	0.000972	CcSEcCtD
Ibandronate—Abdominal pain—Epirubicin—bone cancer	0.000693	0.000971	CcSEcCtD
Ibandronate—Body temperature increased—Epirubicin—bone cancer	0.000693	0.000971	CcSEcCtD
Ibandronate—Hypersensitivity—Methotrexate—bone cancer	0.00069	0.000967	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—bone cancer	0.000672	0.000942	CcSEcCtD
Ibandronate—Feeling abnormal—Doxorubicin—bone cancer	0.000669	0.000937	CcSEcCtD
Ibandronate—Gastrointestinal pain—Doxorubicin—bone cancer	0.000663	0.000929	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—bone cancer	0.000663	0.000929	CcSEcCtD
Ibandronate—Hypersensitivity—Epirubicin—bone cancer	0.000646	0.000905	CcSEcCtD
Ibandronate—Urticaria—Doxorubicin—bone cancer	0.000644	0.000903	CcSEcCtD
Ibandronate—Abdominal pain—Doxorubicin—bone cancer	0.000641	0.000898	CcSEcCtD
Ibandronate—Body temperature increased—Doxorubicin—bone cancer	0.000641	0.000898	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—bone cancer	0.000641	0.000898	CcSEcCtD
Ibandronate—Asthenia—Epirubicin—bone cancer	0.000629	0.000881	CcSEcCtD
Ibandronate—Pruritus—Epirubicin—bone cancer	0.00062	0.000869	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—bone cancer	0.00062	0.000868	CcSEcCtD
Ibandronate—Diarrhoea—Epirubicin—bone cancer	0.0006	0.00084	CcSEcCtD
Ibandronate—Hypersensitivity—Doxorubicin—bone cancer	0.000598	0.000837	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—bone cancer	0.000596	0.000835	CcSEcCtD
Ibandronate—Rash—Methotrexate—bone cancer	0.000591	0.000828	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—bone cancer	0.00059	0.000827	CcSEcCtD
Ibandronate—Headache—Methotrexate—bone cancer	0.000587	0.000822	CcSEcCtD
Ibandronate—Asthenia—Doxorubicin—bone cancer	0.000582	0.000815	CcSEcCtD
Ibandronate—Dizziness—Epirubicin—bone cancer	0.00058	0.000812	CcSEcCtD
Ibandronate—Pruritus—Doxorubicin—bone cancer	0.000574	0.000804	CcSEcCtD
Ibandronate—Vomiting—Epirubicin—bone cancer	0.000557	0.000781	CcSEcCtD
Ibandronate—Nausea—Methotrexate—bone cancer	0.000556	0.00078	CcSEcCtD
Ibandronate—Diarrhoea—Doxorubicin—bone cancer	0.000555	0.000778	CcSEcCtD
Ibandronate—Rash—Epirubicin—bone cancer	0.000553	0.000774	CcSEcCtD
Ibandronate—Dermatitis—Epirubicin—bone cancer	0.000552	0.000774	CcSEcCtD
Ibandronate—Headache—Epirubicin—bone cancer	0.000549	0.000769	CcSEcCtD
Ibandronate—Dizziness—Doxorubicin—bone cancer	0.000536	0.000752	CcSEcCtD
Ibandronate—Nausea—Epirubicin—bone cancer	0.000521	0.00073	CcSEcCtD
Ibandronate—Vomiting—Doxorubicin—bone cancer	0.000516	0.000723	CcSEcCtD
Ibandronate—Rash—Doxorubicin—bone cancer	0.000511	0.000717	CcSEcCtD
Ibandronate—Dermatitis—Doxorubicin—bone cancer	0.000511	0.000716	CcSEcCtD
Ibandronate—Headache—Doxorubicin—bone cancer	0.000508	0.000712	CcSEcCtD
Ibandronate—Nausea—Doxorubicin—bone cancer	0.000482	0.000675	CcSEcCtD
